S-1 plus CIK as second-line treatment for advanced pancreatic cancer

Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer

(2013) Sheng-bin Shi et al.   PANCREATOLOGY

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis

(2012) Yue Ma et al.   CYTOTHERAPY

Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer

(2011) Runbo Zhong et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study

(2011) Christian Bauer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

(2010) B. D. Smith et al.   CLINICAL CANCER RESEARCH

Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan

(2010) Y. Nakai et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure

(2010) A. Todaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

(2008) Chigusa Morizane et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer

(2008) M. K. Kim et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy

(2008) Derrick Wong et al.   PANCREAS